β-Blocker Therapy and Risk of Chronic Obstructive Pulmonary Disease - A Danish Nationwide Study of 1·3 Million Individuals

Medicine & Life Sciences

• Chronic Obstructive Pulmonary Disease 100%
• Hospitalization 46%
• Antihypertensive Agents 45%
• Therapeutics 18%
• Pulmonary Heart Disease 17%
• Pulmonary Circulation 15%
• Disease Susceptibility 13%
• Denmark 13%
• Mortality 12%
• Biomedical Research 12%
• Pulmonary Embolism 12%
• Adrenergic Receptors 11%
• Duration of Therapy 11%
• Proportional Hazards Models 11%
• Myocardial Ischemia 11%
• Cardiac Arrhythmias 10%
• Registries 9%
• Asthma 9%
• Hypertension 8%
• Health 6%